Loading…
Neuland Laboratories (NEULANDLAB)₹20,322+2.45%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Neuland Laboratories reported sales of ₹640 Cr, up 119.4% from Jun 2025, and net profit of ₹148 Cr, up 956.7% year on year. For the year to Mar 2026, sales were ₹2,017 Cr and net profit ₹364 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 417 | 391 | 384 | 439 | 310 | 397 | 327 | 292 | 512 | 438 | 774 | 640 |
| Expenses | 280 | 272 | 278 | 317 | 249 | 312 | 277 | 258 | 359 | 364 | 469 | 419 |
| Operating Profit | 137 | 121 | 107 | 123 | 61.82 | 86.78 | 50.88 | 33.91 | 156 | 76.81 | 306 | 222 |
| OPM % | 33.0% | 31.0% | 28.0% | 28.0% | 20.0% | 22.0% | 16.0% | 12.0% | 30.0% | 18.0% | 40.0% | 35.0% |
| Other Income | 2.99 | 1.99 | 4.99 | 24.97 | 3.99 | 59.90 | 6.99 | 7.99 | 1.99 | 7.99 | 11.98 | 7.99 |
| Interest | 4.01 | 4.01 | 4.01 | 3.01 | 1.01 | 2.01 | 2.01 | 5.01 | 5.01 | 7.01 | 7.01 | 7.02 |
| Depreciation | 15.03 | 15.03 | 16.03 | 16.02 | 16.04 | 16.02 | 17.04 | 20.04 | 23.05 | 24.06 | 25.04 | 27.04 |
| Profit before tax | 122 | 104 | 91.66 | 130 | 48.80 | 128 | 38.87 | 17.94 | 129 | 53.82 | 286 | 197 |
| Tax % | 27.0% | 22.0% | 27.0% | 25.0% | 34.0% | 20.0% | 29.0% | 20.9% | 25.0% | 26.0% | 26.0% | 25.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 15.99 | 0.00 | 43.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 88.99 | 80.99 | 68.03 | 98.05 | 33.02 | 102 | 28.01 | 14.01 | 97.02 | 41.01 | 213 | 148 |
| EPS (Rs) | 69.38 | 63.30 | 52.50 | 76.10 | 25.52 | 78.99 | 21.62 | 10.80 | 75.30 | 31.55 | 165.24 | 114.84 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 508 | 577 | 525 | 665 | 760 | 934 | 948 | 1,186 | 1,553 | 1,473 | 2,017 | 2,364 |
| Expenses | 431 | 473 | 477 | 609 | 662 | 790 | 808 | 920 | 1,097 | 1,148 | 1,444 | 1,612 |
| Operating Profit | 79.75 | 106 | 50.83 | 57.81 | 102 | 146 | 144 | 272 | 462 | 330 | 579 | 761 |
| OPM % | 16.0% | 18.0% | 10.0% | 9.0% | 13.0% | 16.0% | 15.0% | 23.0% | 30.0% | 22.0% | 29.0% | 32.2% |
| Other Income | 1.99 | 0.99 | 3.99 | 2.99 | 3.99 | 15.97 | 0.00 | 8.99 | 11.98 | 89.95 | 24.96 | 29.95 |
| Interest | 24.04 | 21.03 | 19.04 | 16.04 | 22.04 | 18.04 | 14.02 | 13.03 | 14.04 | 8.02 | 24.05 | 26.05 |
| Depreciation | 16.02 | 19.04 | 22.05 | 26.05 | 31.07 | 40.04 | 49.09 | 53.10 | 60.10 | 66.16 | 92.13 | 99.19 |
| Profit before tax | 41.86 | 66.73 | 13.94 | 19.94 | 52.80 | 105 | 81.77 | 215 | 400 | 345 | 487 | 666 |
| Tax % | 36.0% | 30.0% | 13.0% | 19.0% | 69.0% | 23.0% | 22.0% | 24.0% | 25.0% | 25.0% | 26.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.01 | −0.99 | −0.99 | 0.00 | 85.98 | 2.99 | 0.00 |
| Net Profit | 27.02 | 47.02 | 12.01 | 16.01 | 16.01 | 81.07 | 64.01 | 164 | 300 | 260 | 364 | 499 |
| EPS (Rs) | 30.66 | 52.55 | 13.52 | 12.76 | 12.59 | 62.68 | 49.56 | 127.06 | 233.20 | 202.18 | 282.82 | 386.93 |
| Dividend payout % | 7.0% | 0.0% | 0.0% | 0.0% | 16.1% | 8.0% | 10.0% | 8.0% | 6.0% | 6.0% | 12.1% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.97 | 8.97 | 8.97 | 8.98 | 12.96 | 12.96 | 12.96 | 12.96 | 12.95 | 12.95 | 12.95 | 12.95 |
| Reserves | 152 | 178 | 537 | 549 | 687 | 697 | 774 | 828 | 981 | 1,269 | 1,512 | 1,863 |
| Borrowings | 188 | 182 | 191 | 318 | 230 | 263 | 182 | 241 | 128 | 94.70 | 156 | 300 |
| Other Liabilities | 161 | 154 | 147 | 193 | 199 | 257 | 354 | 301 | 455 | 452 | 496 | 751 |
| Total Liabilities | 511 | 523 | 885 | 1,070 | 1,129 | 1,230 | 1,323 | 1,381 | 1,578 | 1,829 | 2,177 | 2,927 |
| Fixed Assets | 123 | 139 | 466 | 475 | 543 | 654 | 717 | 768 | 758 | 824 | 956 | 1,179 |
| CWIP | 40.93 | 39.94 | 19.97 | 126 | 104 | 23.96 | 16.96 | 19.95 | 40.95 | 45.90 | 47.87 | 211 |
| Investments | 7.01 | 7.01 | 8.01 | 8.01 | 8.01 | 8.01 | 7.01 | 4.01 | 1.01 | 1.01 | 109 | 2.01 |
| Other Assets | 339 | 336 | 391 | 462 | 474 | 545 | 582 | 590 | 779 | 958 | 1,064 | 1,536 |
| Inventories | 113 | 127 | 135 | 175 | 192 | 219 | 247 | 264 | 278 | 349 | 385 | 508 |
| Trade receivables | 129 | 119 | 181 | 194 | 164 | 190 | 218 | 233 | 361 | 373 | 315 | 540 |
| Cash & equivalents | 6.98 | 9.97 | 11.97 | 16.96 | 37.87 | 46.87 | 18.93 | 19.93 | 58.86 | 117 | 258 | 354 |
| Total Assets | 511 | 523 | 885 | 1,070 | 1,129 | 1,230 | 1,323 | 1,381 | 1,578 | 1,829 | 2,177 | 2,927 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 13.04 | 45.11 | 39.14 | 11.03 | 70.24 | 57.18 | 190 | 60.20 | 238 | 262 | 318 | 348 |
| Cash from investing activity | −13.95 | −19.92 | −41.87 | −116 | −76.76 | −48.81 | −83.74 | −94.69 | −60.80 | −150 | −297 | −422 |
| Cash from financing activity | 1.01 | −24.07 | 0.00 | 105 | 12.04 | −5.01 | −114 | 38.13 | −136 | −69.25 | 25.09 | 21.06 |
| Net cash flow | 0.00 | 0.99 | −3.99 | 0.00 | 4.99 | 2.99 | −9.01 | 2.99 | 39.97 | 41.96 | 43.98 | −54.95 |
| Capex | 14.95 | 18.93 | 40.88 | 134 | 62.84 | 48.84 | 105 | 97.75 | 65.82 | 144 | 205 | 396 |
| Free cash flow | −1.01 | 26.03 | −2.01 | −121 | 7.01 | 9.01 | 84.13 | −37.01 | 173 | 119 | 112 | −50.04 |
| CFO / OP % | 33.0% | 70.0% | 52.0% | 28.0% | 128.0% | 61.0% | 132.0% | 56.0% | 103.1% | 81.0% | 119.0% | 78.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 99 | 84 | 113 | 133 | 89 | 90 | 84 | 89 | 110 | 86 | 77 | 97 |
| Inventory days | 170 | 182 | 186 | 266 | 191 | 209 | 205 | 227 | 211 | 220 | 238 | 245 |
| Days payable | 168 | 122 | 119 | 190 | 119 | 111 | 127 | 101 | 130 | 122 | 157 | 130 |
| Cash conversion cycle | 103 | 147 | 182 | 211 | 162 | 190 | 164 | 216 | 193 | 187 | 160 | 214 |
| Working capital days | 11 | 26 | 44 | 38 | 138 | 137 | 60 | 74 | 81 | 88 | 76 | 75 |
| ROCE % | 16.0% | 18.0% | 16.0% | 4.0% | 4.0% | 8.0% | 11.0% | 10.0% | 21.0% | 33.0% | 19.0% | 26.0% |
For the Jun 2026 quarter, Neuland Laboratories reported sales of ₹640 Cr, up 119.4% year on year and net profit of ₹148 Cr, up 956.7% year on year. The operating margin was 35.0%.
Neuland Laboratories' sales for the year to Mar 2026 were ₹2,017 Cr; over the last twelve months they were ₹2,364 Cr.
Net profit for the year to Mar 2026 was ₹364 Cr, and ₹499 Cr over the last twelve months. Earnings per share over the same trailing period were ₹386.93.
Neuland Laboratories reported borrowings of ₹300 Cr at Mar 2026, against cash and equivalents of ₹354 Cr.
Cash from operations was ₹348 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹50.04 Cr.